Blueberries Medical Corp. Stocks

CA$ 0.02Last Updated 13.02.2026

Issuer Rating

2/7

Performance

Modest

Risk

Critical

Recommendation

Sell

Market Cap

CA$ 5.46M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CA$ 0.02
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable price performance

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Blueberries Medical Corp. engages in the growth, cultivation, development, production, and supply of medicinal cannabis and related products in Colombia. It offers medicinal-grade cannabis oil extracts and related products. The company is headquartered in Bogotá, Colombia.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks